A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

NCT01204996 ↗

Phase 1 Completed 53 enrolled Centocor, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and dose regimen of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens.

Timeline

Start: 2010-05
Primary completion: —
Completion: 2011-11

Publications

Brana I, Calles A, LoRusso PM, Yee LK, Puchalski TA, Seetharam S, Zhong B, de Boer CJ, Tabernero J, Calvo E. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. 2015 Mar;10(1):111-23. doi: 10.1007/s11523-014-0320-2. Epub 2014 Jun 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	6 unknown	—
Subject	Carlumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Carlumab	Monoclonal antibody	15 mg/kg	Intravenous
Subject	Docetaxel	Small molecule	75 mg/m2	—
Subject	Doxorubicin	Other / unclassified	50 mg/m2	Intravenous
Subject	Gemcitabine	Small molecule	1000 mg/m2	—
Subject	Paclitaxel	Small molecule	175 mg/m2	—

A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

Summary

Timeline

Publications

Drugs

Indications